PGNY — Progyny, Inc.
Is PGNY overbought or oversold? Here is the current MarketMoodz read.
Progyny, Inc. (PGNY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $37.15. The rating moved from Neutral to Overbought on November 14, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$37.15
- Last changeMoved from Neutral to Overbought on November 14, 2026
- SectorHealthcare
- IndustryHealthcare Plans
See all overbought Healthcare stocks →
AI analysis
Progyny operates a differentiated employer-paid fertility and family-building benefits platform with recurring contract revenue and secular demand tailwinds. The company benefits from sticky relationships, clinic partnerships and potential operating leverage, but faces meaningful downside from client concentration, competition, and sensitivity to employer benefits spend. Recent market tone is cautious and focused on policy and earnings signals rather than company-specific catalysts; limited social and filing data in the provided window increases near-term uncertainty. Scenario outcomes range from stable growth if employer adoption and utilization continue to ramp, to margin pressure and slower revenue growth if macro weakness, competitive pricing pressure, or heightened regulatory compliance costs materialize.
Key factors
- Niche, recurring-revenue business model providing fertility and family-building benefits to large employers, driving sticky client relationships and multiyear contracts
- Secular tailwinds: rising employer willingness to offer fertility benefits, delayed parenthood trends, and increasing utilization of assisted reproductive technologies
- Margin profile benefits from managed care model and service coordination, with potential for operating leverage as scale improves
- Exposure to corporate benefits spend and hiring trends which can support demand for Progyny’s solutions in a relatively stable employer market
- Partnerships with clinics, labs and specialty providers that create referral and capture advantages versus fragmented competitors
- Limited near-term market catalysts visible in the provided market window; sentiment is balanced and macro rate-path uncertainty could limit aggressive positioning
Risks
- Concentration risk from large employer clients or brokers — loss or renegotiation of major contracts could materially affect revenue
- Macroeconomic slowdown or hiring freezes that reduce elective procedure volumes and employer benefits expansion
- Competitive pressure from carriers, brokers, and other benefits administrators that could compress pricing or market share
- Regulatory and compliance risk in healthcare broadly (including increased integrity checks and verification) that could raise administrative costs
- Reimbursement and payer negotiation risk if insurers or employers push for more cost control on fertility benefits
- Operational execution risk scaling clinic networks and maintaining quality of outcomes as utilization grows
- Limited visibility on near-term earnings/EDGAR filings in the supplied data increases uncertainty around financial health and guidance
- Potential volatility from sentiment shifts during earnings season or sector rotation into defensives
See today's live rating, score and targets
Members see the live hourly rating for PGNY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.